Source comparison
MC1R Selectivity vs MC3R/MC4R in MT-II Immune Biology
A critical pharmacological consideration for immune researchers is that MT-II engages MC1R, MC3R, MC4R, and MC5R, while endogenous α-MSH and the reference compound [Nle4-D-Phe7]-α-MSH (NDP-MSH) have similar profiles. MC3R is expressed at lower levels in macrop
This comparison does not assign a generated winner or score.
- A critical pharmacological consideration for immune researchers is that MT-II engages MC1R, MC3R, MC4R, and MC5R, while endogenous α-MSH and the reference compound [Nle4-D-Phe7]-α-MSH (NDP-MSH) have similar profiles. MC3R is expressed at lower levels in macrophages than MC1R, but contributes to MT-II’s immune effects in tissues where MC3R expression is relatively higher (adipose-resident macrophages, intestinal macrophages). MC4R in the hypothalamus contributes to MT-II’s well-documented central anti-inflammatory actions in neuroinflammation models. For researchers seeking to attribute MT-II’s peripheral immune effects specifically to MC1R, the selective MC1R agonist BMS-470539 (or γ-MSH for MC3R selectivity) should be used as a mechanistic comparator alongside BMS-470539 as antagonist control.
- The cyclic peptide structure of MT-II (cyclic lactam) confers proteolytic stability and approximately 1000× greater potency than linear α-MSH at MC1R — a pharmacological advantage that makes MT-II the preferred tool compound for studying MC1R-mediated immune biology relative to α-MSH or ACTH fragments.